{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:01:57Z","timestamp":1786982517508,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81370889"],"award-info":[{"award-number":["81370889"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the key research and development plan of Zhenjiang city","award":["SH2022046"],"award-info":[{"award-number":["SH2022046"]}]},{"name":"the key research and development plan of Zhenjiang city","award":["YLJ202101"],"award-info":[{"award-number":["YLJ202101"]}]},{"name":"the key research and development plan of Zhenjiang city","award":["JDYY2023006"],"award-info":[{"award-number":["JDYY2023006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the potential of group I pepsinogen (PG I) and group II pepsinogen (PG II) as diagnostic markers for recurrence in gastric cancer (GC) patients post-total gastrectomy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Ninety-six patients who underwent total gastrectomy for GC between June 2022 and June 2023 were included in this study. Clinical data, serum samples, and ascites samples were collected. Patients were categorized based on recurrence status at the time of sample collection and the primary tumor site. PG I and PG II levels were determined using a chemiluminescent immunoassay, and their clinical utility following total gastrectomy for GC was evaluated via receiver operating characteristic (ROC) curve analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This study included 96 GC patients who underwent total gastrectomy, 55 of whom experienced postoperative recurrence (57.29%). The levels of serum PG I (27.86 (27.04, 30.97) vs. 26.05 (24.16, 27.09) ng\/mL;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and PG II (1.95 (1.23, 3.05) vs. 0.63 (0.47, 0.90) ng\/mL;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001) were significantly greater in the recurrent group compared to the non-recurrent group. The secretion of PG I and\/or PG II by metastatic cancer cells correlated with the primary lesion site. When the cut-off value for serum PG I was 26.93\u00a0ng\/mL, the area under the curve (AUC) for PG I was 0.77. When the cut-off value for serum PG II was 0.96\u00a0ng\/mL, the AUC reached 0.90. The combined AUC was 0.97.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest that serum PG I and PG II are valuable biomarkers for identifying GC patients with biochemical recurrence post-total gastrectomy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12672-024-01091-0","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T10:02:16Z","timestamp":1718618536000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["PG I and PG II show unique value in diagnosing postoperative biochemical recurrence in patients with gastric cancer after total gastrectomy"],"prefix":"10.1007","volume":"15","author":[{"given":"Jiuru","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiameng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqian","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoming","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"issue":"1","key":"1091_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/labmed\/lmab035","volume":"53","author":"XL Han","year":"2022","unstructured":"Han XL, Yi CL, Ma JD, He Y, Wu LM, Wang YF, et al. Clinical value of pepsinogen in the screening, prevention, and diagnosis of gastric cancer. Lab Med. 2022;53(1):71\u20137.","journal-title":"Lab Med"},{"issue":"6","key":"1091_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2169\/internalmedicine.46.6181","volume":"46","author":"C Mukoubayashi","year":"2007","unstructured":"Mukoubayashi C, Yanaoka K, Ohata H, Arii K, Tamai H, Oka M, et al. Serum pepsinogen and gastric cancer screening. Intern Med. 2007;46(6):261\u20136.","journal-title":"Intern Med"},{"issue":"3","key":"1091_CR3","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3904\/kjim.2020.139","volume":"35","author":"YJ Kim","year":"2020","unstructured":"Kim YJ, Chung WC. Is serum pepsinogen testing necessary in population based screening for gastric cancer? Korean J Intern Med. 2020;35(3):544\u20136.","journal-title":"Korean J Intern Med"},{"issue":"7","key":"1091_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2183\/pjab.87.405","volume":"87","author":"K Miki","year":"2011","unstructured":"Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels - \u201cABC method.\u201d Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(7):405\u201314.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"4","key":"1091_CR5","doi-asserted-by":"publisher","first-page":"637","DOI":"10.4149\/neo_2018_180825N647","volume":"66","author":"G Yu","year":"2019","unstructured":"Yu G, Wang GX, Wang HG, Mo FF, Tang BB. The value of detecting pepsinogen and gastrin-17 levels in serum for pre-cancerous lesion screening in gastric cancer. Neoplasma. 2019;66(4):637\u201340.","journal-title":"Neoplasma"},{"issue":"3","key":"1091_CR6","doi-asserted-by":"publisher","first-page":"300060520914826","DOI":"10.1177\/0300060520914826","volume":"48","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhu Z, Liu Z, Zhao Z, Xue X, Li X, et al. Diagnostic value of serum pepsinogen I, pepsinogen II, and gastrin-17 levels for population-based screening for early-stage gastric cancer. J Int Med Res. 2020;48(3):300060520914826.","journal-title":"J Int Med Res"},{"issue":"4","key":"1091_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1177\/03008916211014961","volume":"108","author":"D Trivanovic","year":"2022","unstructured":"Trivanovic D, Plestina S, Honovic L, Dobrila-Dintinjana R, Vlasic Tanaskovic J, Vrbanec D. Gastric cancer detection using the serum pepsinogen test method. Tumori. 2022;108(4):386\u201391.","journal-title":"Tumori"},{"issue":"1","key":"1091_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1515\/bmc-2019-0010","volume":"10","author":"F Mansour-Ghanaei","year":"2019","unstructured":"Mansour-Ghanaei F, Joukar F, Baghaee M, Sepehrimanesh M, Hojati A. Only serum pepsinogen I and pepsinogen I\/II ratio are specific and sensitive biomarkers for screening of gastric cancer. Biomol Concepts. 2019;10(1):82\u201390.","journal-title":"Biomol Concepts"},{"issue":"1","key":"1091_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12893-022-01667-z","volume":"22","author":"C Shibata","year":"2022","unstructured":"Shibata C, Nakano T, Yasumoto A, Mitamura A, Sawada K, Ogawa H, et al. Comparison of CEA and CA19-9 as a predictive factor for recurrence after curative gastrectomy in gastric cancer. BMC Surg. 2022;22(1):213.","journal-title":"BMC Surg"},{"issue":"10","key":"1091_CR10","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1007\/s00595-021-02248-y","volume":"51","author":"J Moriyama","year":"2021","unstructured":"Moriyama J, Oshima Y, Nanami T, Suzuki T, Yajima S, Shiratori F, et al. Prognostic impact of CEA\/CA19-9 at the time of recurrence in patients with gastric cancer. Surg Today. 2021;51(10):1638\u201348.","journal-title":"Surg Today"},{"key":"1091_CR11","first-page":"2455","volume":"9","author":"W Tong","year":"2016","unstructured":"Tong W, Ye F, He L, Cui L, Cui M, Hu Y, et al. Serum biomarker panels for diagnosis of gastric cancer. Onco Targets Ther. 2016;9:2455\u201363.","journal-title":"Onco Targets Ther"},{"issue":"4","key":"1091_CR12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/bjc.2011.592","volume":"106","author":"HS Ahn","year":"2012","unstructured":"Ahn HS, Shin YS, Park PJ, Kang KN, Kim Y, Lee HJ, et al. Serum biomarker panels for the diagnosis of gastric adenocarcinoma. Br J Cancer. 2012;106(4):733\u20139.","journal-title":"Br J Cancer"},{"issue":"3","key":"1091_CR13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s12029-018-0091-6","volume":"50","author":"B Ghaderi","year":"2019","unstructured":"Ghaderi B, Moghbel H, Daneshkhah N, Babahajian A, Sheikhesmaeili F. Clinical evaluation of serum tumor markers in the diagnosis of gastric adenocarcinoma staging and grading. J Gastrointest Cancer. 2019;50(3):525\u20139.","journal-title":"J Gastrointest Cancer"},{"key":"1091_CR14","doi-asserted-by":"publisher","first-page":"8087","DOI":"10.2147\/IJGM.S335985","volume":"14","author":"Z Wang","year":"2021","unstructured":"Wang Z, Mo TM, Tian L, Chen JQ. Gastrin-17 combined with CEA, CA12-5 and CA19-9 improves the sensitivity for the diagnosis of gastric cancer. Int J Gen Med. 2021;14:8087\u201395.","journal-title":"Int J Gen Med"},{"issue":"1","key":"1091_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12893-021-01063-z","volume":"21","author":"Z Xing","year":"2021","unstructured":"Xing Z, Qiu Y, Li Z, Zhang L, Fei Y, Zhu J, et al. Predictors of thyroglobulin in the lymph nodes recurrence of papillary thyroid carcinoma undergoing total thyroidectomy. BMC Surg. 2021;21(1):53.","journal-title":"BMC Surg"},{"issue":"17","key":"1091_CR16","doi-asserted-by":"publisher","first-page":"7038","DOI":"10.18632\/aging.204270","volume":"14","author":"Y Cai","year":"2022","unstructured":"Cai Y, Zeng R, Peng J, Liu W, He Q, Xu Z, et al. The downregulated drug-metabolism related ALDH6A1 serves as predictor for prognosis and therapeutic immune response in gastric cancer. Aging. 2022;14(17):7038\u201351.","journal-title":"Aging"},{"issue":"24","key":"1091_CR17","doi-asserted-by":"publisher","first-page":"14467","DOI":"10.1111\/jcmm.16069","volume":"24","author":"Y Sheng","year":"2020","unstructured":"Sheng Y, Han C, Yang Y, Wang J, Gu Y, Li W, et al. Correlation between LncRNA-LINC00659 and clinical prognosis in gastric cancer and study on its biological mechanism. J Cell Mol Med. 2020;24(24):14467\u201380.","journal-title":"J Cell Mol Med"},{"issue":"4","key":"1091_CR18","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/0284186X.2021.1874619","volume":"60","author":"J Asplund","year":"2021","unstructured":"Asplund J, Gottlieb-Vedi E, Leijonmarck W, Mattsson F, Lagergren J. Prognosis after surgery for gastric adenocarcinoma in the Swedish Gastric Cancer Surgery Study (SWEGASS). Acta Oncol. 2021;60(4):513\u201320.","journal-title":"Acta Oncol"},{"issue":"5","key":"1091_CR19","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1001\/jamasurg.2022.0182","volume":"157","author":"GZ Li","year":"2022","unstructured":"Li GZ, Doherty GM, Wang J. Surgical management of gastric cancer: a review. JAMA Surg. 2022;157(5):446\u201354.","journal-title":"JAMA Surg"},{"issue":"4","key":"1091_CR20","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s10555-020-09925-3","volume":"39","author":"RE Sexton","year":"2020","unstructured":"Sexton RE, Al Hallak MN, Diab M, Azmi AS. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev. 2020;39(4):1179\u2013203.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"1091_CR21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3322\/caac.21657","volume":"71","author":"SS Joshi","year":"2021","unstructured":"Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264\u201379.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1091_CR22","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1097\/SLA.0000000000003833","volume":"275","author":"Y Cao","year":"2022","unstructured":"Cao Y, He H, Li R, Liu X, Chen Y, Qi Y, et al. Latency-associated peptide identifies immunoevasive subtype gastric cancer with poor prognosis and inferior chemotherapeutic responsiveness. Ann Surg. 2022;275(1):e163\u201373.","journal-title":"Ann Surg"},{"issue":"6","key":"1091_CR23","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1007\/s10120-021-01207-3","volume":"24","author":"Z Li","year":"2021","unstructured":"Li Z, Jia Y, Zhu H, Xing X, Pang F, Shan F, et al. Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy. Gastric Cancer. 2021;24(6):1342\u201354.","journal-title":"Gastric Cancer"},{"key":"1091_CR24","doi-asserted-by":"publisher","first-page":"1324247","DOI":"10.3389\/fsurg.2023.1324247","volume":"10","author":"BO St\u00fcben","year":"2023","unstructured":"St\u00fcben BO, Plitzko GA, Stern L, Li J, Neuhaus JP, Treckmann JW, et al. Prognostic factors of poor postoperative outcomes in gastrectomies. Front Surg. 2023;10:1324247.","journal-title":"Front Surg"},{"issue":"Suppl 1","key":"1091_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10120-016-0661-x","volume":"20","author":"K Fujiya","year":"2017","unstructured":"Fujiya K, Tokunaga M, Makuuchi R, Nishiwaki N, Omori H, Takagi W, et al. Early detection of nonperitoneal recurrence may contribute to survival benefit after curative gastrectomy for gastric cancer. Gastric Cancer. 2017;20(Suppl 1):141\u20139.","journal-title":"Gastric Cancer"},{"issue":"10","key":"1091_CR26","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1002\/cam4.3899","volume":"10","author":"JS Park","year":"2021","unstructured":"Park JS, Choe EA, Park S, Nam CM, Hyung WJ, Noh SH, et al. Detection of asymptomatic recurrence improves survival of gastric cancer patients. Cancer Med. 2021;10(10):3249\u201360.","journal-title":"Cancer Med"},{"issue":"10","key":"1091_CR27","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/j.1349-7006.1988.tb01537.x","volume":"79","author":"SC Huang","year":"1988","unstructured":"Huang SC, Miki K, Sano J, Ichinose M, Kawamura N, Oka H, et al. Pepsinogens I and II in gastric cancer: an immunohistochemical study using monoclonal antibodies. Jpn J Cancer Res. 1988;79(10):1139\u201346.","journal-title":"Jpn J Cancer Res"},{"issue":"3","key":"1091_CR28","first-page":"159","volume":"3","author":"GN Stemmermann","year":"1985","unstructured":"Stemmermann GN, Samloff IM, Hayashi T. Pepsinogens I and II in carcinoma of the stomach: an immunohistochemical study. Appl Pathol. 1985;3(3):159\u201363.","journal-title":"Appl Pathol"},{"issue":"1","key":"1091_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/BF01670552","volume":"14","author":"M Kodama","year":"1990","unstructured":"Kodama M, Koyama K, Tsuburaya Y, Ishikawa K, Koyama H, Narisawa T, et al. Group I pepsinogen for early detection of gastric cancer recurrence after total gastrectomy. World J Surg. 1990;14(1):94\u2013100.","journal-title":"World J Surg"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01091-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-024-01091-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01091-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T10:02:51Z","timestamp":1718618571000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-024-01091-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1091"],"URL":"https:\/\/doi.org\/10.1007\/s12672-024-01091-0","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,17]]},"assertion":[{"value":"12 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by\u00a0the Ethics Committee at the Affiliated Hospital of Jiangsu University (Approval number: KY2023K0603) and adhered to the ethical principles outlined in the Declaration of Helsinki with utmost diligence.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic approval and consent participate"}},{"value":"The authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}